CareDx and 10x Genomics to launch ImmuneScape to advance transplant rejection research
CareDx, Inc. – The Transplant Company – announced a strategic collaboration with 10x Genomics to establish ImmuneScape, a multiomics research initiative designed by CareDx to elucidate the biology of transplant organ rejection and therapeutic response. Insights generated from this program are intended to support future clinical diagnostic development.
CareDx will leverage 10x’s Xenium spatial and Chromium Flex single cell platforms for this initiative, which aims to generate high-resolution maps of the complex immune mechanisms underlying organ rejection associated with AMR and MVI. These data may help characterize disease origin and trajectory, as well as therapeutic response, laying the groundwork for future breakthroughs with potential to advance personalized transplant medicine.
ImmuneScape will build on CareDx’s ongoing efforts to deepen biological understanding in transplantation by mapping immune cell populations and pathways that distinguish mechanisms of disease origin and inform treatment selection, prognosis, and therapeutic response. CareDx recently introduced HistoMap Kidney, a tissue biopsy-based gene expression classifier designed to refine rejection subtyping and inform therapeutic management. The collaboration further extends this effort by examining how tissue-level immune architecture may correlate with clinical outcomes, including response to emerging therapies such as anti‑CD38 treatments.
CareDx researchers and clinical collaborators will utilize 10x’s Xenium and Chromium Flex platforms to assess gene expression signatures and immune pathways that may contribute to the observed heterogeneity in transplant patient outcomes. These 10x platforms were selected for the program because they enable high‑resolution profiling of complex immune biology across large cohorts, with the throughput and consistency required to support large‑scale analysis of FFPE biopsy samples for ImmuneScape.
